Phase 1Data readout

NKX019 (CAR NK Therapy)

Rheumatoid Arthritis

NKTXNkarta Therapeutics

Expected catalystDecember 31, 2026Company guidance: Dec 31, 2026

Catalyst overview

Event details

Drug or asset: NKX019 (CAR NK Therapy)
Development stage: Phase 1
Event type: Data readout
Indication: Rheumatoid Arthritis

Research summary

What is being tracked?

This catalyst tracks a Phase 1 data readout for NKX019 (CAR NK Therapy) in Rheumatoid Arthritis. The expected timing is based on the latest available company guidance and may change.

Development notes

08/10/26:- Ntrust trials enroll rheumatoid arthritis; initial data expected in 2026.

Verification

Primary source

Confirm timing and program details against the company announcement or filing.

Open source

NKX019 (CAR NK Therapy)

Event details

What is being tracked?

Development notes

Primary source

Related pipeline programs

NKX019 (CAR NK cell therapy)

NKX019 (CAR NK cell therapy)

NKX019 (CAR NK Therapy)